LEO Pharma announce the completion of the Phase III FIELD Study 1, evaluating one year treatment outcomes of actinic keratosis
LEO Pharma has announced the completion of the Phase III FIELD Study 1 - the largest[1-3] ever, one year evaluation of field treatment with ingenol mebutate gel for actinic keratosis (AK) after initial cryosurgery of individual AK lesions, compared to cryosurgery followed by a vehicle gel.